Emergent plots $75M expansion to produce viral vectors for expanding gene therapy business

SourceFierce Pharma
Date Published06/18/2020
Author NameKyle Blankenship
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Emergent BioSolutions
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2023
Capital investment ($):75
City reshored to:Canton
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredviral vectors for vaccines
What domestic positive factors made reshoring more attractive?Government Incentives, covid-19
Find Reshoring Articles